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Abstract
Background: During preeclampsia, placental angiogenesis is impaired. Factors released from the placenta
including vascular endothelial growth factor (VEGF), placental growth factor (PLGF), soluble VEGF receptor 1 (sFlt1),
and soluble endoglin (sEng) are regulatory molecules of placental development and function. While the renin
angiotensin system has been shown to regulate angiogenic factors in other research fields, these mechanisms
have not been extensively studied during pregnancy.
Methods: We evaluated the effects of angiotensin II (Ang II) and angiotensin-(1-7) [Ang-(1-7)] on the release of
VEGF, PLGF, sFlt1, and sEng from placental chorionic villi (CV). CV were collected from nulliparous third-trimester
normotensive and preeclamptic subjects. CV were incubated for 0, 2, 4, and 16 hours with or without Ang II (1 nM
and 1 microM) or Ang-(1-7) (1 nM and 1 microM). The release of VEGF, PLGF, sFlt1, sEng, lactate dehydrogenase
(LDH), and human placenta lactogen (HPL) was measured by ELISA.
Results: The release of sFlt1, PLGF, sEng from normal and preeclamptic CV increased over time. Release of sFlt1
and sEng was significantly higher from preeclamptic CV. VEGF was below the detectable level of the assay in
normal and preeclamptic CV. After 2 hours, sFlt1 release from normal CV was significantly inhibited with Ang II (1
nM and 1 microM) and Ang-(1-7) (1 nM and 1 microM). There was a time-dependent increase in HPL indicating
that the CV were functioning normally.
Conclusions: Our study demonstrates a critical inhibitory role of angiotensin peptides on sFlt1 in normal
pregnancy. Loss of this regulation in preeclampsia may allow sFlt1 to increase resulting in anti-angiogenesis and
end organ damage in the mother.
Background
Preeclampsia, clinically defined by the new onset of
hypertension and proteinuria after 20 weeks gestation of
pregnancy, affects 7-10% of pregnancies in the United
Sates, 2-5% in European countries and over 10% in
developing countries. Additionally, preeclampsia is
responsible for large numbers of maternal and neonatal
morbidity and mortality [1]. While the causes of pree-
clampsia remain unclear, significant advances have been
made in understanding normal placental vasculogenesis
and the pathophysiology of preeclampsia. It is thought
that a balance of pro-angiogenic and anti-angiogenic
factors modulate vessel growth in the placenta through-
out pregnancy. Vascular endothelial growth factor
(VEGF) and placental growth factor (PLGF) are pro-
angiogenic molecules that act through two high affinity
receptors, VEGF receptor 1 (VEGFR1 or Flt-1) and
VEGF receptor 2 (VEGFR2 or KDR/Flk-1) [2,3]. In pree-
clampsia, the ischemic placenta has been shown to
release factors, including the anti-angiogenic molecules
soluble fms-like tyrosine kinase 1 (sFlt1) [4] and soluble
endoglin (sEng) [5], that result in vasoconstriction and
the end organ damage seen in the mother [6-8]. sFlt1,
the soluble form of VEGFR1, can act as a decoy recep-
tor by binding and sequestering circulating VEGF and
PLGF thus preventing these molecules from binding to
their active membrane bound endothelial cell receptors
and consequently inhibiting angiogenesis [9]. Endoglin is
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(TGF-b1a n dT G F - b3) and has been shown to be
expressed in endothelial cells and syncytiotrophoblasts
[10-12]. sEng, a novel placenta derived soluble form of
endoglin (Eng), is an anti-angiogenic protein that has
been shown to inhibit TGF-b1 receptor binding leading
to dysregulation of TGF-b1 signaling in the vasculature
[5]. It has recently been shown that sFlt1 and sEng act-
ing through different pathways work in concert to
induce severe preeclampsia [5]. The molecular mechan-
isms that regulate sFlt1 release may also regulate sEng
release from the preeclamptic placenta, however, the
upstream regulators of these anti-angiogenic proteins
remains unknown.
The RAS is an endocrine circulating system that is
responsible for blood pressure, salt and fluid homeosta-
sis. During normal pregnancy the RAS is activated due
to increased estrogen levels which consequently cause
levels of angiotensinogen [13,14] and renin [15-18] to
rise. In association with the increases in angiotensino-
gen and renin, angiotensin II (Ang II) is up-regulated.
The recently discovered peptide of the RAS, angioten-
sin-(1-7) [Ang-(1-7)] [19,20], has been shown in pre-
vious studies to increase in the circulation in the third
trimester of pregnancy [21] and in urine throughout
pregnancy [22]. A balance of the two biologically active
peptides of the RAS, Ang II, a vasoconstrictor and
angiogenic molecule, and Ang-(1-7), a vasodilator and
anti-angiogenic molecule, may be essential for the
maintenance of normal pregnancy. Previous studies
done in our laboratory have investigated circulating and
local RAS component expression in normal and pree-
clamptic women. While plasma angiotensin I (Ang I),
Ang II, Ang-(1-7), and plasma renin activity are
decreased in the circulation of preeclamptic women
[21], in the chorionic villi of preeclamptic placentas,
Ang II peptide levels and angiotensinogen and AT1
receptor mRNA levels were increased [23]. These find-
ings in the chorionic villi of preeclamptic placentas lead
us to hypothesize that Ang II and Ang-(1-7) might be
regulators of sFlt1 and sEng release in preeclampsia.
Although not much is known about the interaction
between the RAS and angiogenic growth factors during
pregnancy, Ang II has been shown to regulate angio-
g e n e s i st h r o u g ha l t e r a t i o n si nV E G Fe x p r e s s i o ni nt h e
non-pregnant state [24-28]. Even less is known about
the regulation of RAS peptides on the newly discovered
modulators of placental angiogenesis such as sFlt1 and
sEng. Therefore, in this study, we investigated the effect
of Ang II and Ang-(1-7) on the release of sFlt1, sEng,
VEGF, PLGF, and human placental lactogen (HPL)
(functional control) from normal and preeclamptic
chorionic villous explants.
Methods
Human subjects
These experiments were conducted using human pla-
cental tissue collected from woman with both normal
pregnancies and preeclampsia. Placental tissue was col-
lected from women who had either cesarean section or
vaginal deliveries. Two separate groups of subjects were
included. Group 1 (n = 21) consisted of normotensive
pregnant subjects who have remained normotensive
throughout pregnancy (systolic/diastolic BP < 140/90
mmHg), have no history of chronic blood pressure ele-
vation, and have an absence of proteinuria. Group 2 (n
= 15) consisted of preeclamptic subjects who developed
new onset hypertension (systolic/diastolic BP > 140/90
mmHg) and proteinuria (1+ or equivalent to 30 mg/dl)
proteinuria or ≥ 300 mg in 24 hour urine sample) after
the 20
th week of gestation. Blood pressure readings are
reported as the highest blood pressure measured in the
labor and delivery suite prior to delivery. Subjects in the
two groups were matched according to gestational age
and parity (all nulliparous). Patients with evidence of
chorioamnionitis were excluded. Women in both groups
were over age 18 years and less than age 50 years and
were free of other known cardiovascular, renal, connec-
tive tissue diseases, diabetes, cancer, or hyperplasia.
The study was approved by the institutional review
boards (IRB) at both Wake Forest University School of
Medicine and Forsyth Medical Center. The procedures
followed were in accordance with institutional guide-
lines. After signed informed consent was obtained and
the baby and placenta were delivered, placental samples
were taken.
Experimental procedures
For both normal pregnant and preeclamptic patients,
immediately following delivery, the whole placenta was
collected on ice and large tissue sections were taken
from the center of the placenta, near the umbilical cord
attachment site and at the periphery of the placenta.
More specifically, five tissue sections were collected
from each placenta. One piece of tissue was collected
directly adjacent to the umbilical cord insertion site.
The placenta was then divided into four quadrants
where one piece of tissue from the periphery of the pla-
centa was collected per quadrant. Areas of fibrotic
lesions, heavy calcification and blood clotting were
avoided. The total amount of time from delivery of the
placenta until the samples were collected did not exceed
fifteen minutes. The placental tissues were extensively
washed in sterile phosphate buffered saline and placed
on ice in a nutrient rich media containing high glucose
Dulbecco’s Modified Eagle’s Medium (DMEM), 2.5%
FBS, and antibiotics, for transport to the lab. The
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the chorionic villi in a serum free media made up of
low glucose DMEM/F-12, non-essential amino acids
(NEAA), glucose, sodium pyruvate, L-gluatamine, lino-
leic acid, NaHCO3, ex-cyte enhancement media supple-
ment (Millipore, Billerica, MA), and antibiotics.
Human placental chorionic villous explant culture
Chorionic villi (1.0 gram) dissected from human placen-
tal tissues taken from normal pregnant and preeclamptic
women were placed into 25 ml Erlenmeyer flasks con-
taining 10 ml of serum free media. The flasks were
placed into a Dubnoff metabolic shaking bath (Precision
Scientific, Winchester, VA) under constant shaking at
37°C in a humidified atmosphere of 5% N2 (pO2 in
media = 60 mm Hg) supplemented with 5% CO2 [29].
Under normal physiological conditions, the oxygen ten-
sion within the intervillous space at term is ~50 to 60
mm Hg [30,31]. After 15 minutes of incubation, the
amount of oxygen in the media was analyzed using a
Rapidlab 248 blood gas machine (Bayer HealthCare,
East Walpole, MA). The pO2 and pCO2 were monitored
throughout the experiment to ensure a consistent gas
environment. The tissue was cultured in the metabolic
shaker for 2 hours as an equilibration period. The media
was removed and 5 ml of fresh serum free media treated
w i t ho rw i t h o u t1n Mo r1μM Ang II or Ang-(1-7) was
added to the villous explants. In addition, normal and
preeclamptic chorionic villi (n = 4) were incubated in
serum free media plus cell lysis buffer in order to evoke
a maximal amount of LDH release. Values were
expressed as percent of maximal release. The chorionic
villi were incubated for 0, 2, 4, or 16 hours. The media
was collected and frozen at -80°C for further analysis.
The chorionic villous tissue was weighed and a small
piece was removed and placed in 4% formaldehyde for
histological analysis.
Enzyme linked immunoassay (ELISA)
VEGF, PLGF, sFlt1, sEng, and human placental lactogen
(HPL) released into the cell culture media from normal
pregnant and preeclamptic chorionic villi explants were
measured by ligand specific commercially available
ELISA kits that utilize a quantitative sandwich enzyme
immunoassay technique using regents from R&D Sys-
tems (Minneapolis, MN) for VEGF, PLGF, and sFlt1,
a n ds E n g .F o rH P L ,ak i tf r o mA l p c oD i a g n o s t i c s
(Windham, NH) was used.
Lactate dehydrogenase (LDH) in vitro toxicology assay
LDH released into the media from normal and preeclamp-
tic chorionic villi throughout the chorionic villi explant
experiment was measured by a commercially available
LDH in vitro toxicology kit (Sigma, St. Louis, MS).
Statistical analysis
The data were analyzed with a two way analysis of var-
iance (ANOVA). When there was a significant interac-
tion, subsequent analysis included the Bonferroni’sp o s t
hoc test for multiple comparisons to determine the
effects between time points and treatment groups. The
Student’s t test for unpaired observations was used for
comparing two groups (GraphPad Software, San Diego,
CA). All data were normally distributed. A p value of
less than 0.05 was considered statistically different. All
arithmetic means are presented ± standard deviation
(SD).
Results
Clinical profile of normal and preeclamptic patients
Table 1 shows the clinical characteristics of the 21
women with normal pregnancies and the 15 women
with preeclampsia for this study. The preeclamptic
women had significant hypertension with increased sys-
tolic, diastolic, and mean blood pressures. In addition,
the preeclamptic subjects showed proteinuria measured
as greater than 1+ or equivalent to 30 mg/dl on a urine
dipstick. The preeclamptic subjects also had a signifi-
cantly lower birth weight than normal pregnant women.
No significant differences were seen in maternal age or
body mass index. The normal and preeclamptic subjects
were matched for gestational age.
Time dependent release of sFlt1, sEng, PLGF, VEGF, and
HPL from normal and preeclamptic chorionic villi explants
The time dependent release of sFlt1, sEng, PLGF, and
HPL from normal and preeclamptic chorionic villi
explants was measured at 0, 2, 4, and 16 hours of incu-
bation as shown in Figure 1. The concentration of sFlt1
was significantly increased over time (p < 0.0001) at 2
(p < 0.05), 4 (p < 0.01), and 16 (p < 0.001) hours in
both normal and preeclamptic chorionic villi. In addi-
tion, sFlt1 at 16 hours was significantly different from 2
(p < 0.001) and 4 (p < 0.001) hours in normal and pree-
clamptic chorionic villi. The concentration of sFlt1 was
significantly higher in the preeclamptic subjects (p <
0.0001) at 2 (p < 0.05), 4 (p < 0.05), and 16 (p < 0.05)
hours (Figure 1A).
The concentration of sEng was significantly increased
over time (p < 0.0001) in normal and preeclamptic chor-
ionic villi. sEng was significantly increased from baseline
(0 hours) at 4 (p < 0.01) and 16 (p < 0.01) hours in pre-
eclamptic chorionic villi and only at 16 hours (p < 0.05)
in normal chorionic villi. In addition, sEng was signifi-
cantly higher (p < 0.01) in preeclamptic explants when
compared to normal pregnant women at 2 (p < 0.01)
and 4 (p < 0.05) hours (Figure 1B).
The concentration of PLGF from normal and pree-
clamptic chorionic villi was significantly increased over
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Patient clinical characteristics Normal pregnancy Preeclamptic pregnancy
n 21 15
Age (years) 26.3 ± 5.9 23.7 ± 4.5
Body Mass Index (BMI) (kg/m2) 29.8 ± 6.3 29.6 ± 4.6
Birth weight (grams) 3035.4 ± 535.0 2599 ± 697.3
a
Gestational age(weeks) 37.8 ± 2.1 s36.6 ± 2.4
Systolic blood pressure (mm Hg) 135 ± 13 174 ± 15
b
Diastolic blood pressure (mm Hg) 77 ± 9 110 ± 7
b
Mean blood pressure (mm Hg) 96 ± 9 131 ± 8
b
Proteinuria (0-4+) none >1+
Number of patients receiving anti-hypertensive medications none 5
Values are expressed as mean ± SD.
ap<0 . 0 5 ,
bp < 0.0001 versus normal pregnancy
‡Anti-hypertensive treatment for five preeclamptic patients included Hydralazine and Labetalol.
Figure 1 Time dependent release of sFlt1, sEng, PLGF, and HPL.s F l t 1( A), sEng (B), PLGF (C), and HPL (D) release were measured in the
media after 0, 2, 4, and 16 hours of incubation in normal (n = 21) and preeclamptic (n = 15) chorionic villous explants. Data are expressed as
the mean ± SD. * p < 0.05 preeclamptic versus normal chorionic villi, # p < 0.05 relative to 0 hours, ∞ p < 0.05 relative to 2 hours, and ≠ p<
0.05 relative to 4 hours in either normal or preeclamptic chorionic villi explants.
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(p < 0.001) hours. In addition, PLGF at 16 hours was
significantly different from 2 (p < 0.001) and 4 (p <
0.05) hours only in the preeclamptic chorionic villi. No
differences in PLGF were seen between normal and pre-
eclamptic chorionic villi at each time point (Figure 1C).
VEGF from normal and preeclamptic chorionic villi
was found to be below the detectable level of the assay
at all time points (0-16 hours) (data not shown).
In these experiments, we measured the release of HPL
from the chorionic villi as a positive control of tissue
function to ensure that the chorionic villi remained intact
and continued to produce HPL over time. The concen-
tration of HPL was significantly increased over time from
0 to 16 hours in both normal and preeclamptic chorionic
villi (p < 0.0001). HPL was significantly increased from
baseline (0 hours) at 4 (p < 0.01) and 16 (p < 0.01) hours
in normal and preeclamptic chorionic villi. HPL at 16
hours was significantly different from both 2 (p < 0.001)
and 4 (p < 0.05) hours in the preeclamptic chorionic villi.
In normal chorionic villi, the concentration of HPL at 16
hours was significantly different after 4 hours (p < 0.01)
of incubation. No significant differences in HPL were
seen between normal and preeclamptic chorionic villi at
each time point (Figure 1D).
In order to monitor the integrity of the chorionic villi,
LDH was measured as an index of chorionic villi degra-
dation and breakdown throughout the time course of
the experiment. Maximal release of LDH (1090 ± 156
U/L) was elicited by incubating the chorionic villi with
cell lysis buffer. The basal concentration of LDH in the
media at 2 and 4 hours was only 5% and 7% of maximal
release, respectively and not significantly different from
the 0 time point. At 16 hours, LDH levels were less
than 15% of the maximal cell lysis buffer evoked LDH.
There was no difference in LDH concentration between
normal and preeclamptic chorionic villi except for a
slightly higher level at 2 hours in the preeclamptic sam-
ples (data not shown). Additionally, investigation of the
chorionic villi histology after 16 hours of incubation
showed no changes in tissue morphology or evidence of
tissue damage (data not shown).
The effect of Ang II and Ang-(1-7) on the release of sFlt1
in normal and preeclamptic chorionic villi
Normal and preeclamptic chorionic villi were treated
with Ang II and Ang-(1-7) (1 nM and 1 μM )f o r0 ,2 ,4 ,
and 16 hours and the amount of sFlt1 released into the
media was measured. As seen in Figure 2A, after 2
hours of incubation, sFlt1 release was significantly inhib-
ited by treatment with 1 nM Ang II (p < 0.01), 1 μM
Ang II (p < 0.05), 1 nM Ang-(1-7) (p < 0.01), and 1 μM
A n g - ( 1 - 7 )( p<0 . 0 1 )i nt h ec h o r i o n i cv i l l if r o mn o r m a l
pregnant women. After 4 hours of incubation, sFlt1
release is still significantly inhibited by 1 nM Ang II (p
<0 . 0 5 )a n d1μM Ang II (p < 0.05) in the normal chor-
ionic villi (Figure 2B). However, treatment with Ang-(1-
7) no longer significantly inhibits sFlt1 release from nor-
mal chorionic villi. Ang II and Ang-(1-7) had no effect
on sFlt1 release in the preeclamptic chorionic villi at
any time point.
The effect of Ang II and Ang-(1-7) on the release of PLGF
and sEng in normal and preeclamptic chorionic villi
Normal and preeclamptic chorionic villi were treated
with Ang II and Ang-(1-7) (1 nM and 1 μM )f o r0 ,2 ,4 ,
and 16 hours and the amount of PLGF and sEng
released into the media was measured. PLGF (Figure 3A
and 3B) and sEng (data not shown) released from nor-
mal and preeclamptic chorionic villi was unchanged
after Ang II (1 nM and 1 μM) or Ang-(1-7) (1 nM and
1 μM) treatment for 2 and 4 hours. In addition, no sig-
nificant changes were seen in PLGF or sEng release by
Ang II (1 nM and 1 μM) or Ang-(1-7) (1 nM and 1
μM) treatment in normal or preeclamptic chorionic villi
at 16 hours (data not shown).
Discussion
This study demonstrates that sFlt1, sEng, PLGF, and
HPL are released from the chorionic villi of both normal
and preeclamptic women and that the release of sFlt1 is
regulated by Ang II and Ang-(1-7). We found that sFlt1
and sEng release from the chorionic villi is higher in
preeclamptic women when compared to normal. Both
Ang II and Ang-(1-7) decreased the release of sFlt1
from the chorionic villi of normal pregnant women but
not from women with preeclampsia after two hours of
incubation. In addition, we found that sEng, PLGF, and
HPL release from both normal and preeclamptic chorio-
nic villi was unchanged with Ang II and Ang-(1-7) treat-
ment. This study provides evidence that the biologically
active renin angiotensin system peptides, Ang II and
Ang-(1-7), are involved in regulating the release of the
anti-angiogenic growth factor, sFlt1, from the chorionic
villi in normal but not preeclamptic pregnancies.
Ang II and Ang-(1-7) decreased sFlt1 release from normal
chorionic villous explants
In normal chorionic villi, sFlt1 was significantly
decreased by both Ang II and Ang-(1-7) after 2 hours of
incubation. While Ang II continued to cause a signifi-
cant decrease in sFlt1 release after 4 hours of treatment,
there was no longer a significant Ang-(1-7) mediated
effect. By 16 hours there was no significant effect on
sFlt1 release by Ang II or Ang-(1-7). A previous study
investigated the effects of Ang II on sFlt1 release in nor-
mal human placental villous explants and found that
Ang II treatment after 48 and 72 hours increased sFlt1
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the two studies may be explained by the differences in
experimental length. While the human placental villous
explant studies done by Zhou et al. [32] involved Ang II
treatment over a period of 48 and 72 hours, our study
was never longer than 16 hours and showed significant
effects of Ang II on sFlt1 release as early as two hours.
Therefore, the regulation of sFlt1 release by Ang II may
be critically time dependent.
We monitored the stability of the chorionic villous tis-
sue throughout the experiment. Basal levels of LDH
release never reached higher than 5-7% of the cell lysis
evoked LDH levels at the early time points of incubation
(2 and 4 hours) where the observed effects of Ang II
and Ang-(1-7) on sFlt1 release were seen. The study by
Zhou et al [32] did not provide any measurements of
the stability of the placental villous explants at the 48
and 72 hour time points. LDH levels measured in our
chorionic villi explants incubated for 48 and 72 hours
were greater than 20% of the maximal LDH release
(data not shown). This may indicate that the increased
sFlt1 release shown by Zhou et al. [32] could be asso-
ciated with tissue damage from the longer incubation
time and could contribute to the differences between
the findings. Investigation of the histology of the chorio-
nic villi in both normal and preeclamptic subjects
revealed no damage or abnormalities to the tissue dur-
ing the 16 hours of incubation (data not shown). HPL, a
measurement of tissue function, showed an increasing
trend at 2 hours and a significant increase at 4 hours.
Therefore, the decrease in sFlt1 release by Ang II and
Ang-(1-7) in our study occurs when there is no evidence
Figure 2 The effects of Ang II and Ang-(1-7) on sFlt1 release at 2 hours and 4 hours of incubation. Normal (n = 21) and preeclamptic (n
= 15) chorionic villi were incubated with or without Ang II (1 nM and 1 μM) or Ang-(1-7) (1 nM and 1 μM) and sFlt1 release was measured by
ELISA after 2 hours (A) and 4 hours (B) of incubation. Data are expressed as the mean ± SD. * p < 0.05 versus control of normal chorionic villi.
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rity by the release of HPL.
The Ang II-mediated decrease in sFlt1 release in nor-
m a lc h o r i o n i cv i l l ii sf u r t h er corroborated by previous
studies which have shown that Ang II initiates angiogen-
esis by decreasing sFlt1 release and consequently caus-
i n ga ni n c r e a s ei nf r e eV E G F .B o t hA n gI Ia n dA n g - ( 1 -
7) have been shown to act as regulators of the angio-
genic process through alterations in VEGF production.
Ang II, acting through the AT1 receptor, can induce the
over expression of VEGF causing an increase in angio-
genesis [24-28]. Interestingly, we have previously shown
that the AT1 receptor is the predominant angiotensin
receptor subtype present in the chorionic villi of the pla-
centa by both real time RT-PCR and in vitro receptor
autoradiography [23] indicating that Ang II would most
likely be acting through the AT1 receptor to decrease
sFlt1 release. Therefore, it can be hypothesized that dur-
ing normal pregnancy Ang II decreases sFlt1 release
allowing unbound VEGF and PLGF to initiate the angio-
genic process and contribute to endothelial function, a
potentially beneficial effect for normal pregnancy.
The decrease in sFlt1 release after treatment with
Ang-(1-7) (1 nM and 1 μM) in normal chorionic villi
was unexpected since previous studies have shown that
Ang-(1-7) acts primarily as an anti-angiogenic protein.
Our laboratory has shown that Ang-(1-7) inhibits in
vitro tube formation in human umbilical vein endothe-
lial cells (HUVEC) [33]. Ang-(1-7) also inhibits angio-
genesis and fibrovascular tissue growth in cultured rat
thoracic aortic vascular smooth muscle cells and in a
mouse sponge model of angiogenesis [34,35]. More
recent studies have shown that Ang-(1-7) inhibits lung
tumor formation and growth [36]. The specific effects of
Figure 3 The effects of Ang II and Ang-(1-7) on PLGF release at 2 hours and 4 hours of incubation. Normal (n = 9) and preeclamptic (n
= 15) chorionic villi were incubated with or without Ang II (1 nM and 1 μM) or Ang-(1-7) (1 nM and 1 μM) and PLGF release was measured by
ELISA after 2 hours (A) and 4 hours (B) of incubation. Data are expressed as the mean ± SD.
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studied so the role of Ang-(1-7) in the angiogenic pro-
cess in the placenta is unknown. The finding that both
Ang II and Ang-(1-7) inhibited the release of sFlt1 is
unusual since their actions are in most instances oppo-
site. However, an early study reported that Ang II and
Ang-(1-7) have similar effects by increasing arginine
vasopressin release from rat hypothalmic explants [37].
There is a possibility that the high dose (1 μM) of Ang-
(1-7) could be acting at the AT1 receptor and could;
therefore, be causing Ang II-like actions of decreased
sFlt1 release. However, activation of the AT1 receptor at
a lower dose (1 nM) of Ang-(1-7) would be unlikely. It
has been previously shown that Ang-(1-7) has a poor
affinity for the AT1 receptor [38,39]. Therefore, this
w o u l ds u g g e s tt h a tA n g - ( 1 - 7 )i sa c t i n ga ti t so w ns p e c i -
fic AT1-7 receptor. The fact that Ang II and Ang-(1-7)
both decrease sFlt1 release in normal chorionic villi
does provide strong evidence that the RAS is an impor-
tant mediator of angiogenesis in the placenta.
Loss of Ang II and Ang-(1-7) regulation on sFlt1 release
from preeclamptic chorionic villi
Investigation of sFlt1 in preeclamptic chorionic villi
showed a significant increase in release when compared
to normal chorionic villi over the time course of the
experiment. Our results agree with several previous stu-
dies where sFlt1 protein levels were found to be up-
regulated in the placenta of women with preeclampsia
[4,40,41]. No changes in sFlt1 release from preeclamptic
chorionic villi were seen with treatment of either Ang II
or Ang-(1-7). This result indicates that the regulation
seen with Ang II and Ang-(1-7) on sFlt1 release in the
normal chorionic villi is lost in women with preeclamp-
sia. The loss of sFlt1 regulation in the preeclamptic pla-
centa provides evidence for the fact that sFlt1 would be
released into the circulation uninhibited in the presence
of Ang II and Ang-(1-7), where it can bind to both
VEGF and PLGF thus blocking them from binding to
their membrane bound receptors and preventing the
downstream signaling cascades needed to initiate angio-
genesis. The decrease in angiogenesis caused by the loss
of Ang II and Ang-(1-7) regulation within the placenta
could be contributing to the placental ischemia seen in
women with preeclampsia.
sEng release was unchanged by Ang II and Ang-(1-7) in
normal and preeclamptic chorionic villi
Along with sFlt1, we investigated the effects of Ang II
and Ang-(1-7) treatment on sEng release from normal
and preeclamptic chorionic villi. We found a significant
increase in sEng release from preeclamptic chorionic
villi when compared to normal at the 2 hour and 4 hour
time points. In agreement with our results, sEng has
been shown in previous studies to be up-regulated in
the placenta of preeclamptic women [5]. No changes in
sEng release were seen with Ang II and Ang-(1-7) treat-
ment in normal and preeclamptic chorionic villi. The
fact that sEng release was not changed with either Ang
II or Ang-(1-7) treatment, while both peptides had an
effect on sFlt1 release indicates that the renin angioten-
sin system may play a more predominant role in regu-
lating angiogenesis through sFlt1 rather than sEng. Even
though sFlt1 and sEng act in concert to control the
mechanisms that may be responsible for the develop-
ment of preeclampsia, each of these anti-angiogenic
molecules may be regulated differently. Therefore, addi-
tional studies investigating the upstream molecular regu-
lators of sEng are warranted.
VEGF and PLGF release were unchanged by Ang II and
Ang-(1-7) in normal and preeclamptic chorionic villi
In addition to sFlt1 and sEng release, we investigated
VEGF and PLGF release from normal and preeclamptic
chorionic villi. VEGF release was found to be below the
detectable level of the assay in both normal and pree-
clamptic chorionic villi at all time points measured.
While circulating VEGF levels have been measurable in
the serum of normal and preeclamptic women, they
w e r ef o u n dt ob ev e r yl o w[ 4 , 4 0 ] .C o n t r a r yt oo u r
results, a previous study using human placental explants
was able to measure VEGF release after 24 hours of
incubation [29]. These conflicting results could be due
to the fact that the study done by Ahmed and Ahmed
[29] incubated their tissues in a smaller amount of
media allowing the concentration of VEGF release to be
measurable. The very low amounts of VEGF released by
the chorionic villi indicate that PLGF may be the more
predominant pro-angiogenic growth factor in the pla-
cental chorionic villi during pregnancy. In this study we
found that there was a trend for a decrease in PLGF
release in the control (non-treated) preeclamptic chorio-
nic villi when compared to normal at the two hour time
point, however it did not reach statistical significance.
These results agree with previous studies that have
shown that PLGF release is decreased in association
with increases in sFlt1 in preeclamptic women [4,40,42].
Treatment of normal and preeclamptic chorionic villi
with Ang II and Ang-(1-7) had no effects on PLGF
release. No previous studies have been done to investi-
gate the effects of Ang II on PLGF. Although our results
show that Ang II and Ang-(1-7) did not have an effect
on PLGF regulation in the chorionic villi, the presence
of PLGF in this tissue indicates that this angiogenic fac-
tor could be playing an important role in balancing the
anti-angiogenic effects of sFlt1 during normal preg-
nancy. In women with preeclampsia, where sFlt1 release
is significantly higher and PLGF release is unchanged or
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anti-angiogenesis resulting in decreased blood vessel
growth within the placenta.
Interestingly, the concentrations of sFlt1 and sEng
release were about 1000 times higher than PLGF release
in both normal and preeclamptic chorionic villi. This
indicates that sFlt1 and sEng may be the predominant
factors in angiogenesis regulation within the placenta.
However, this does not rule out an effect of PLGF
release on the angiogenic balance in normal and pree-
clamptic patients. In normal pregnancy, the decrease in
sFlt1 release from the chorionic villi by Ang II and Ang-
(1-7) would be consistent with increased levels of free
VEGF and PLGF and their subsequent effects on
angiogenesis.
Conclusions
This study provides evidence that the RAS components,
Ang II and Ang-(1-7), play a role in controlling the
release of angiogenic growth factors from chorionic villi.
Both Ang II and Ang-(1-7) decrease sFlt1 release in nor-
mal chorionic villi but not in the chorionic villi from
preeclamptic women. Because the regulation of sFlt1 is
critical to the process of angiogenesis, our data suggest
that the down-regulation of sFlt1 release by Ang II and
Ang-(1-7) in normal chorionic villi may decrease the
amount of sFlt1 available to bind to VEGF and PLGF
and promote their actions on angiogenesis. In women
with preeclampsia, where we have shown Ang II levels
to be increased in the chorionic villi [23], the regulation
of Ang II on sFlt1 is lost causing the release of sFlt1 to
be uninhibited contributing to an enhanced state of
anti-angiogenesis.
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